The Woodlands, TX, and St. Louis, MO, March 14, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies. [Read more…]
Fujifilm Investing $200M to Expand CDMO Services and Double Capacity for iPSC-derived Therapeutics
The investment will double FUJIFILM Cellular Dynamics’s manufacturing capacity for iPSC-derived cell therapies for its partners. New headquarters will include iPSC manufacturing for drug discovery, drug efficacy, and pharmacology applications.
FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, CA, will be expanded to support cell therapy CDMO services.
ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes
Liege, Belgium – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, today announces the worldwide launch of ExoXpertTM, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials. ExoXpert is a wholly owned subsidiary of EXO BiologicsTM. [Read more…]
Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients
SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer
€30M Series A financing will advance a novel, off-the-shelf gene therapy (AT-108) that directly reprograms tumor cells into antigen-presenting dendritic cells.
Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses.
Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
- « Previous Page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- …
- 336
- Next Page »